GlassScriptPhysician profile
Philip Fortunato Spadafora
NPI 1255386959
$3,100.14
in general payments reported to CMS, 2019-2025
24 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $638 · 2020: $488 · 2021: $647 · 2022: $534 · 2023: $357 · 2024: $236 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $632.33 | 2019-2025 | Rinvoq, Qulipta |
| Astrazeneca Pharmaceuticals LP | $488.80 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $427.70 | 2019-2022 | |
| Glaxosmithkline, LLC. | $399.64 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Genzyme Corporation | $229.03 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $164.68 | 2019-2021 | |
| Pfizer INC. | $77.39 | 2019-2022 | |
| Amgen INC. | $73.44 | 2019-2025 | Repatha |
| Ibsa Pharma INC. | $71.12 | 2022-2023 | Tirosint, Licart |
| Biohaven Pharmaceutical Holding Company LTD. | $67.67 | 2022 | |
| Bausch Health US, LLC | $64.18 | 2021-2025 | Aplenzin |
| Janssen Pharmaceuticals, INC | $57.56 | 2019-2021 | |
| Novo Nordisk INC | $45.60 | 2023-2024 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $42.88 | 2023-2024 | Cologuard Collection Kit |
| Hikma Pharmaceuticals USA | $42.33 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $38.35 | 2023-2024 | Mounjaro |
| Endo Pharmaceuticals INC. | $35.77 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $26.91 | 2023 | Seglentis, Livalo |
| Dexcom, INC. | $23.89 | 2023 | Dexcom G6 Transmitter |
| Evoke Pharma, INC. | $21.57 | 2024 | |
| Abbott Laboratories | $20.98 | 2022 | |
| Intuity Medical INC | $18.39 | 2022 | |
| Genentech USA, INC. | $15.42 | 2019 | |
| Promius Pharma LLC | $14.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Spadafora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.